Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
Biosimilars Make Routine Prophylaxis With G-CSF Feasible in HER2+ Breast Cancer
The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
New Management Strategies Seek to Improve Quality of Life for Patients With Lymphedema
Melanie Taylor, APRN, and Mark Lin, APRN, share how they optimize strategies in caring for patients with lymphedema.
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses
Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.
FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer
The FDA has approved capivasertib plus fulvestrant to treat patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.
Pembrolizumab Is Approved for Patients With HER2– Gastric/GEJ Adenocarcinoma
The FDA has approved pembrolizumab plus chemotherapy to treat adults with locally advanced or metastatic, HER2-negative gastric cancers.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC